KEGG   DRUG: Bimekizumab
Entry
D11550                      Drug                                   

Name
Bimekizumab (USAN/INN);
Bimekizumab (genetical recombination) (JAN)
Formula
C6552H10132N1750O2029S42
Exact mass
147137.1715
Mol weight
147227.7921
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYNMAWVRQA PGKGLEWVAT ITYEGRNTYY
RDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCASPP QYYEGSIYRL WFAHWGQGTL
VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KKVEPKSCDK THTCPPCPAP
ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV
DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
(Light chain)
AIQLTQSPSS LSASVGDRVT ITCRADESVR TLMHWYQQKP GKAPKLLIYL VSNSEIGVPD
RFSGSGSGTD FRLTISSLQP EDFATYYCQQ TWSDPWTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H152-H208, H228-L214, H234-H'234, H237-H'237, H269-H329, H375-H433, H'22-H'96, H'152-H'208, H'228-L'214, H'269-H'329, H'375-H'433, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Efficacy
Antipsoriatic, Anti-IL-17A/IL-17F antibody
Comment
Monoclonal antibody
Treatment of moderate to severe plaque psoriasis
Target
IL17A [HSA:3605] [KO:K05489]
IL17F [HSA:112744] [KO:K05494]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04657  IL-17 signaling pathway
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL17A
     D11550  Bimekizumab (USAN/INN)
    IL17F
     D11550  Bimekizumab (USAN/INN)
Other DBs
CAS: 1418205-77-2
PubChem: 384585526
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system